Hosted on MSN26d
Sensorion’s Phase I/II gene therapy trial to continue with DMC recommendation
The programme is aimed at treating a certain congenital deafness form caused by otoferlin (OTOF) gene mutations. SENS-501’s intra-cochlear administration was tolerated well, allowing the second ...
Business Wire1mon
Sensorion Receives Positive Recommendation from Data Monitoring Committee of SENS-501’s Audiogene Phase 1/2 Clinical Trial
The Audiogene trial is designed to evaluate the safety, tolerability and efficacy of intra-cochlear injection of SENS-501 for the treatment of OTOF gene-mediated hearing loss in paediatric ...
pharmaphorum3d
Sensorion encouraged by deafness gene therapy data
The preliminary results from the Audiogene study, conducted in children aged six to 31 months without cochlear hearing implants, also showed that the SENS-501 (formerly OTOF-GT) gene therapy was ...
Business Insider26d
Latest DB-OTO Results Demonstrate Clinically Meaningful Hearing Improvements in Nearly All Children with Profound Genetic Hearing Loss in CHORD Trial
In addition to OTOF, Regeneron is committed to investigating several other targets for genetic forms of hearing loss, including GJB2. Regeneron (NASDAQ: REGN) is a leading biotechnology company ...
pharmaphorum5d
Regeneron dials up in gene therapy with Decibel deal
The main focus of the deal is Decibel's DB-OTO, an adeno-associated virus (AAV) gene therapy designed to correct mutations in the otoferlin or OTOF gene, which codes for a large protein expressed ...
Pharmabiz26d
Sensorion receives DMC recommendation to continue the Audiogene phase 1/2 trial of SENS-501
The Audiogene trial is designed to evaluate the safety, tolerability and efficacy of intra-cochlear injection of SENS-501 for the treatment of OTOF gene-mediated hearing loss in paediatric patients ...
Morningstar26d
Latest DB-OTO Results Demonstrate Clinically Meaningful Hearing Improvements in Nearly All Children with Profound Genetic Hearing Loss in CHORD Trial
However, otoferlin-related hearing loss is ultra-rare. This specific condition is caused by variants in the OTOF gene, which leads to a lack of a functional otoferlin protein that is critical for ...